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Abstract 
In recent years, increasing evidence has been collated on the contributions of fungal species, 
particularly Candida, to medical device infections. Fungal species can form biofilms by themselves or 
by participating in polymicrobial biofilms with bacteria. Thus, there is a clear need for effective 
preventative measures, such as thin coatings that can be applied onto medical devices to stop the 
attachment, proliferation, and formation of device-associated biofilms. 
However, fungi being eukaryotes, the challenge is greater than for bacterial infections 
because antifungal agents are often toxic towards eukaryotic host cells. Whilst there is extensive 
literature on antibacterial coatings, a far lesser body of literature exists on surfaces or coatings that 
prevent attachment and biofilm formation on medical devices by fungal pathogens. Here we review 
strategies for the design and fabrication of medical devices with antifungal surfaces. We also survey 
the microbiology literature on fundamental mechanisms by which fungi attach and spread on 
natural and synthetic surfaces. Research in this field requires close collaboration between 
biomaterials scientists, microbiologists and clinicians; we consider progress in the molecular 
understanding of fungal recognition of, and attachment to, suitable surfaces, and of ensuing 
metabolic changes, to be essential for designing rational approaches towards effective antifungal 
coatings, rather than empirical trial of coatings. 
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1.0 Introduction 
The usage of medical devices continues to increase rapidly and they have become essential 
components of modern health-care. Artificial hip and knee implants, stents, heart valves, vascular 
grafts, and other implanted devices are widely used to save lives and to restore function and quality 
of life for large numbers of patients. There is also a need for non-implanted, shorter-term- usage 
medical devices, such as various catheters, orthopedic fixation screws, and contact lenses. Clinical 
needs have given rise to a substantial biomedical devices industry and to an extensive body of 
research in biomaterials science, device design, and clinical studies of devices. 
While usage has increased, there are continuing problems and shortfalls with current devices. 
Improved materials, device designs, and surgical practice have overcome some of the challenges, but 
others remain, including that of device-associated infections. Microbial organisms are capable of 
colonizing the surfaces of a wide range of synthetic materials used to fabricate medical devices. In 
fact, microbial organisms seem to be able to grow and form infectious biofilms on just about any 
material, from metals to ceramics to polymers, even including materials and devices as biologically 
foreign as Teflon™ and silicone hydrogel contact lenses. Microbial biofilm colonies produce an 
exocellular polysaccharide matrix that can protect them against antibiotics and the host body’s innate 
defense system. Biofilms on biomedical device surfaces are, therefore, much more difficult to 
eradicate by antibiotics than circulating microbes, often resulting in the need for surgical revision of a 
substantial proportion of infected implants. 
The bacterial colonization of medical devices is usually pictured as comprising several stages 
(Stoodley et al., 2002) and has been studied extensively. More recently it has become evident that 
fungal species can also form biofilms on biomedical devices, either by themselves or in conjunction 
with bacteria. The formation of fungal biofilms is conceptually similar to that of bacteria; however, 
some important differences are apparent (Soll and Daniels, 2016). An illustration is given in Figure 1. 
Initially, microbial (fungal) cells arrive at the device surface and attach, driven by their propensity to 
settle onto a solid substrate rather than remaining in the planktonic state. Once a sufficient number 
of cells is attached, intercellular communication causes a switch in phenotype resulting in the 
production of extracellular matrix and biofilm formation (Mitchell et al., 2016). With biofilms of 
polymorphic yeasts such as Candida, yeast cells develop pseudohyphae and hyphae creating a 
filamentous layer that extends away from the basal layer of cells (Gulati and Nobile, 2016). As the 
biofilm grows and matures, it eventually starts to release planktonic cells.  The  formation  of  an  
infectious  biofilm  on  the  medical  device  interferes  with  healing,  for  example tissue integration 
of hip and knee implants. The release of microbial cells from the biofilm leads to bloodstream 
infections, which can be lethal for patients severely weakened by surgery or trauma, or that are 
immunocompromised. The situation is further complicated by the fact that with implantable devices, 
detection usually only occurs when a full-blown infectious biofilm has formed on the medical device; 
often the only viable remedy is revision surgery and replacement of the device. 
 
 
Figure 1. Schematic of fungal biofilm formation typical of Candida albicans. 1) In the adhesion phase, 
cells adhere firmly to the substrate. 2) Cells replicate, begin to secrete extracellular matrix and 
develop pseudohyphae. 3) The mature biofilm develops with hyphal filaments extending away from 
a basal layer of yeast-forms. 4) Yeast cells disperse from the biofilm and spread, disseminating the 
infection and beginning the cycle again. 
Accordingly, research has focused on preventing the initial attachment of microbial cells 
onto the surfaces of materials used for medical devices. In particular, the development of thin 
coatings that can be applied to medical devices to confer resistance to microbial colonization has 
been of much interest. Such coatings are designed to prevent the establishment of infectious 
biofilms while not affecting material properties such as the visual clarity of contact lenses or the 
flexibility of vascular grafts. Nor should, of course, such coatings have adverse effects on cells or 
fluids (e.g., blood, tear fluid) of the human host. 
For many years, device-associated infections have been discussed in terms of bacterial 
biofilm formation. In recent years, however, evidence has accumulated that fungal species often 
play a major role (Coad et al., 2016; Coad et al., 2014; Imbert, 2016; Kojic and Darouiche, 2004; Luis 
et al., 1989; Muakkassa and Ghannoum, 2016; Peleg et al., 2010). Pathogenic fungi, particularly 
various Candida species, can form biofilms of their own or associate with bacteria in polymicrobial, 
poly-Kingdom biofilms. Detection and identification of fungal species are more difficult than for 
human pathogenic bacteria, which have been well-known for a long time to microbiologists. This 
may be why fungal contributions to device infections were overlooked for quite some time, and why 
infections at times did not respond well to the administration of antibacterial drugs – after the 
bacteria were killed, fungal organisms were unimpeded by competition and continued to flourish. It 
is therefore clear that there is a need to address the prevention of fungal colonization in the design 
of infection-resistant coatings for medical devices. 
Here we review the literature on strategies on the design of antifungal coatings and the 
resulting outcomes. Strategies for combatting biofilms on surfaces (i.e. antimicrobial materials, 
surfaces, and coatings) are a hot topic in materials-led research, but the large majority focuses on 
antibacterial strategies. In order to be clinically useful, they must be effective in assisting the body to 
clear infection, and must be non-harmful to the patient. With fungal biofilms, or poly-Kingdom 
biofilms, the challenge is also considerable, but not insurmountable, we posit. What is required are 
approaches that are specifically directed to combatting fungi without damaging mammalian cells 
and tissue; this is a considerably more difficult challenge than preventing bacterial biofilm formation 
since fungi are eukaryotic organisms and thus much closer biologically to human cells than bacteria 
are, being prokaryotic. Ultimately one may need to implement dual-action coatings that can combat 
both fungi and bacteria, but for the present review we focus on antifungal strategies. We also 
emphasize strategies that aim to inhibit fungal attachment instead of eradication, as it appears 
challenging to kill fungi without affecting human cells. After an overview of fungal infections on 
medical devices, we will review materials science strategies for preventing colonization. Our aim is 
to stimulate critical thinking and rational design of strategies towards advances in antifungal 
coatings that will ameliorate the problem of fungal infections on medical devices. 
2.0 Fungal infections on medical devices 
2.1 Fungal pathogens contribute to poly-Kingdom biofilm infections, and scope for resistance 
Biofilms on medical device surfaces have a recognized importance in clinical infections. It is 
estimated that 65 % of all microbial infections in humans involve biofilms (Ramage et al., 2006). The 
physical nature of the biofilm, which is a structured microbial community encapsulated within a 
protective extracellular matrix, means that cells within a biofilm display phenotypic traits that are 
vastly different to those found when the cells are in a planktonic state (Costerton et al., 1995). 
Bacterial species are a primary cause of device related infections; however, biofilms are 
communities of organisms and the contributions of many different bacterial species in biofilm 
infections have been recognized (Peters et al., 2012). Moreover, the important role that fungi play in 
biofilms either alone or participating in poly-Kingdom infections is much less well-understood. On 
the specific topic of medical devices with infections derived from, or contributed by fungi, there 
have been a few reviews (Kojic and Darouiche, 2004; Pierce et al., 2015; Ramage et al., 2006; 
Williams et al., 2016).  
Polymicrobial biofilms on indwelling medical devices are multifaceted and difficult to treat 
(Qu et al., 2015). This problem is partly due to the complex interplay between surfaces, bacterial and 
fungal colonizers, and their biological and physical interactions. For example, C. albicans hyphae can 
form a scaffold, which supports and protects S. aureus (Qu et al., 2015). This behaviour is particularly 
a problem due to the fact that these microbial species are frequently encountered in the clinical 
setting, and associated with high mortality rates such as that in catheter-related line bloodstream 
infections (CLBSI) (Sievert et al., 2013). Treatment of polymicrobial biofilms is challenging due to the 
difference in cellular make-up, metabolism, and biochemical pathways in prokaryotic and eukaryotic 
organisms. Therefore, there is a lack of clinically relevant therapies which are capable of killing both 
(Qu et al., 2015). Thus, common antimicrobial therapies used to combat these infections often use 
multiple classes of drugs, but fail to be effective, having a 70 % failure rate (Kim et al., 2013). 
Biofilms are associated with contributing to antibacterial resistance (Costerton et al., 
1999). The same is true for fungal biofilms and their resistance to antifungal agents (Borghi et al., 
2016). For mixed (fungal/bacterial) polymicrobial biofilms there is evidence showing that the 
scope for resistance development is potentially more threatening than monomicrobial biofilms. 
For example, biofilms containing C. albicans and S. aureus are associated with increased bacterial 
resistance to vancomycin and daptomycin, more so than single species biofilms (Harriott and 
Noverr, 2009). This observation is also mirrored for resistance to antifungals where it has been 
shown that Staphylococcus epidermidis (S. epidermidis) can protect C. albicans against fluconazole 
and amphotericin B in a co-cultured biofilm (Adam et al., 2002). Clearly, the role that fungi 
play in biofilms, the treatment difficulties, and their increased potential to develop resistance are 
key issues. 
2.2 Causative fungal species and review of occurrence 
The most frequently used devices that can develop Candida spp. infections are urinary 
catheters, central and peripheral venous catheters, endotracheal tubes, and dentures, which are 
used in the millions of units per year (Kojic and Darouiche, 2004; Ramage et al., 2006). The infection 
risk on these devices is variable, but the pervasiveness of the problem can be seen in urinary 
catheters, which had a usage rate of tens of millions of units used in 2006 and an associated 
infection risk between 10 and 30 %. Other biomaterials that are prone to fungal infections include 
prosthetic joints, intracardiac prosthetic devices, haemodialysis and peritoneal dialysis catheters, 
breast implants, neurosurgical shunts, voice prostheses, and penile implants. Other yeast species, 
such as Cryptococcus, Trichosporon, and Saccharomyces, have also been described in case reports to 
infect biomaterial implants (Ramage et al., 2009). 
Risk of infection, site of implantation and life expectancy of the medical device directly 
impacts the opportunity of combatting fungal biofilms on these surfaces. Prosthetic implants have 
around a 1 % chance of developing a Candida spp. infection, despite being deeply implanted and 
designed to last the life span of the patient (Kojic and Darouiche, 2004). Therefore, strategies that 
reduce the risk of infection are attractive, as correction of infected deep implant medical devices is 
directly associated with intensive surgery, high healthcare costs and poor patient outcomes. 
Conversely, usage of voice prostheses is relatively low (thousands of units per year) yet the 
infection risk approaches certainty (50 – 100 %) (Ramage et al., 2006). This prevalence 
demonstrates a great need for anti-infective strategies to suit many devices and usages. 
Yeasts belonging to genus Candida are the primary causative agents for fungal biomaterials 
infections and can disseminate as fungal blood sepsis (candidemia). In 2006, a three-year 
surveillance study explored candidemia-related mortality rates across all Australian intensive care 
units. It was found that greater than 50 % of the patients with candidemia had died as a direct result 
from their Candida spp. systemic infection. Of the 179 patients, C. albicans was detected in 62 % of 
cases (111 people), and C. glabrata in 18 % of cases (32 people) (Playford et al., 2008). Besides 
yeasts, filamentous fungi belonging primarily to Aspergillus spp. have also been known to contribute 
to infections on medical devices and form biofilms. Williams and Ramage have reviewed Aspergillus 
biofilms and describe serious infections that have developed on catheters, prosthetic devices, pace 
makers, heart valves, and breast implants (Williams et al., 2016). The therapeutic strategies to 
address biofilms of Aspergillus fumigatus have also recently been reviewed (Muakkassa and 
Ghannoum, 2016). Finally, Fusarium spp. is associated with the wearing of contact lenses, which can 
lead to fungal keratitis. Strategies that reduce fungal proliferation on lenses and in cleaning solutions 
would help to combat eye diseases and blindness (Imamura et al., 2008).  
2.3 Medical device materials 
Fungal biofilms can develop on a wide variety of implantable devices and, by implication, 
biomaterials, including contact lenses, prosthetic implants, dentures and cochlear implants. A recent 
in vitro study explored biofilm formation of five different Candida spp. (C. albicans, C. glabrata, C. 
parapsilosis, C. tropicalis and C. krusei) on three clinically significant materials, PVC, Teflon™ and 
polyurethane. It was found that all Candida spp. readily formed biofilms on Teflon™, except C. 
glabrata, which exhibited greater biofilm formation on PVC (Estivill et al., 2011). Hence, one has to 
consider the context of both the colonising species and the material properties. An in vitro study 
conducted in 2005 investigated altering the surface chemistries of substrates through the addition of 
surface-modifying end groups (SMEs), in order to prevent or reduce C. albicans biofilm growth 
(Chandra et al., 2005). The results showed that various SMEs affected C. albicans biofilm formation 
differently. For example, Elasthane 80A surfaces modified with 6 % polyethylene oxide reduced 
metabolic activity of C. albicans biofilm by 78 % (Chandra et al., 2005). These different rates of 
colonization, depending on the material, add an additional dimension to this already complex 
problem.   
2.4 Clinical manifestations 
A list of all clinical case studies involving infected implants is beyond the scope of this 
review. Instead, we provide four examples illustrating the clinical significance of fungi-related device 
infections. We contrast strategies for treating devices that are easily removed (such as contact 
lenses or dentures) versus implanted devices such as prosthetics and cochlear implants which are 
designed for long term implantation within the body. While biofilms on short-term devices can be 
treated by cleaning or removal of established biofilms, there is a greater emphasis on prevention 
in the case of implanted device. 
A review by Ramage et al. provides an excellent summary table of medical implant devices 
that develop Candida-derived infections, their usage and infection risk (Ramage et al., 2006). In Table 
1 we present a summary of information for the four examples shown below. This is meant to provide 
insight into common and less-common fungal infections on various biomaterial implant devices and 
their clinical significance related to this context.     
 
Table 1. The clinical significance and causative agents of fungal infections pertaining to a 
















Dentures are one of the most common medical implant 
devices associated with fungal infections. 
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Although rare, fungal prosthetic infections are difficult 
to combat with surgical techniques, and expected to 





C. albicans When the cause of implant infections is unknown, the 
use of antibacterial prophylaxis can eliminate bacterial 
pathogens but is ineffectual against fungal pathogens. 
 
2.4.1 Dentures 
Accounting for device usage and infection risk, dentures are one of the most common 
biomaterial devices causing fungal infections (Ramage et al., 2006). Dental plaque frequently 
forms on these devices and the importance of fungi in these polymicrobial biofilms is recognized. For 
example, Peleg et al., explored the symbiotic relationship between Streptococcus spp. and C. 
albicans in the oral cavity. The results suggest that the presence of the bacteria promotes 
adhesion of fungal cells, as the bacteria are capable of adsorbing protein components from the 
saliva, which encourage C. albicans adhesion (Peleg et al., 2010). The onset of denture-induced 
stomatitis from polymicrobial biofilms can result in oral candidiasis where C. albicans is the primary 
organism responsible (Chandra et al., 2005; Estivill et al., 2011), while C. glabrata, C. parapsilosis and 
C. tropicalis infections occur at a lower incidence (Nett et al., 2010). Fungal biofilms formed on 
denture surfaces are common, however, effective methods of control are currently not understood. 
Preventing these will require a better understanding of how Candida spp. in particular adhere onto 
the various polymeric substances that comprise denture materials. These polymers are mostly 
acrylic hybrids consisting of a mixture of polymethyl methacrylate (PMMA), hydroxyapatite or 
polyamide resin, polyurethane, polycarbonateurethane and poly(ethyleneterephthalate) (PET) (de 
Freitas Fernandes et al., 2011; Pereira-Cenci et al., 2008; Von Fraunhofer et al., 1988). Additionally, 
the supportive framework of dentures is composed of hybrid acrylic resins (PMMA, hydroxyapatite, 
polyamide resin) or a flexible polymer, such as nylon (de Freitas Fernandes et al., 2011). 
A study conducted in 2007 described the physical properties of denture materials that affect 
Candida spp. adhesion to materials surfaces. Such properties include surface free energy, surface 
roughness and presence of saliva. This in vitro study concluded that overall adhesion and 
colonization of C. albicans and C. glabrata on materials surfaces was reduced by saliva, surface 
roughness, and bacteria, but not by surface free energy (Pereira et al., 2007). Another study 
conducted by the same group in 2008 explored the interactions between C. albicans, C. glabrata and 
Streptococcus mutans in biofilms, when in the presence of saliva. The materials used for test 
substrates were hydroxyapatite, PMMA and soft denture liner. It was concluded that saliva, 
substrate material and the presence of other microorganisms, significantly affected Candida spp. 
biofilm growth (Pereira-Cenci et al., 2008). 
Removal of established biofilms on dentures is possible by manual cleaning or soaking in 
cleansers. In 2011, a study aimed to evaluate the efficacy of current denture cleansers against fungal 
and polymicrobial biofilms grown on polyamide resin with different surface roughness and surface 
free energy. Candida spp. biofilms were grown on PMMA resin and polyamide resin before being 
treated with either enzymatic cleaner solution, a cleanser solution, 0.5% sodium hypochlorite 
solution or water. Ultrasonic waves were used to remove any remaining adhered fungal cells, and 
these were plated up and colony-forming units were counted. Polyamide resins were shown to 
support higher Candida spp. biofilm growth than PMMA materials, with all cleanser solutions 
removing Candida spp. biofilms on both PMMA and polyamide resin materials. The cleanser solution 
composed of 0.5 % sodium hypochlorite was concluded to be the most effective cleanser (de Freitas 
Fernandes et al., 2011).  
2.4.2 Contact lenses 
Fungal keratitis refers to opportunistic fungal infection and inflammation of the cornea and 
was first described in 1879 (Cheng et al., 2015; Hassan et al., 2010; Leber, 1879). Fungal keratitis is 
caused by Candida spp., Aspergillus spp. and Fusarium spp., with the latter being the most common. 
If left untreated, fungal keratitis can lead to endophthalmitis and blindness (Cheng et al., 2015). 
Currently, a limited range of topical antifungal agents exists for treatment. The most common 
treatments include topical amphotericin B, topical natamycin, topical fluconazole, oral ketoconazole, 
and recently added, topical and systemic voriconazole (Cheng et al., 2015). A 2015 review of fungal 
keratitis highlighted the major challenge is finding a most suitable drug or combination of drugs for 
effective treatment (Cheng et al., 2015). Fungal keratitis is often incorrectly diagnosed and treated, 
at times resulting in corneal grafting to restore vision. Occasionally, antifungal drug treatment and 
corneal grafting are undertaken prior to establishing a correct diagnosis (Hassan et al., 2010).  
Although fungal infections related to contact-lens use are rare, a marked increase in risk 
associated with contact lens use was evident from 2005, increasing from 40% to 52% (Iyer et al., 
2006). Because loss of eyesight is a devastating outcome of fungal keratitis, it is important to 
investigate disease causes and possible preventative measures associated with contact lenses 
(Imamura et al., 2008). 
Outbreaks associated with increased contact lens use are an interesting case study. The US 
Centers for Disease Control and Prevention received 164 confirmed reports of Fusarium keratitis 
beginning June 2005 until June 2006, spanning 33 states of the USA. It was found that the outbreak 
was directly associated with the use of a particular contact lens solution, and consequently contact 
lens users were urged to stop using that solution (Alfonso et al., 2006; Chang et al., 2006).  
It is important to develop appropriate assays to understand the role of materials and their 
properties in contact lens associated keratitis. Imamura et al. have explored models for contact-lens 
associated fungal biofilms and characterized biofilm formation on soft contact lenses, focussing on 
Fusarium spp. and C. albicans. That study provided important insights into future prevention of 
contact-lens related infections by providing insights into the influence of lens type, and susceptibility 
of lens care solutions to contribute to infections (Imamura et al., 2008).  
2.4.3 Total joint arthroplasty 
A case report in 1998 examined prevalence of fungal infections in total joint arthroplasties. It 
concluded that fungal infections in total joint arthroplasties were rare, with only 21 cases previously 
reported in the literature, most of these caused by Candida spp. However, the limited success rate in 
combatting these infections was evident with all of the cases having to be removed in order to 
eliminate the source of fungal infection (Brooks and Pupparo, 1998). Furthermore, re-implantation 
was reported to be an unsuccessful option. An important virulence factor in periprosthetic infection 
is the ability for C. albicans to form biofilm (Azzam et al., 2009). Due to its persistence, surgical 
treatments involving irrigation and debridement are sometimes unsuccessful, which shows that 
surface attachment to the device and in tissues surrounding the device needs to be considered. The 
incidence of all infections for implanted prosthetic devices is expected to rise with the ageing 
population. Based on data from the United States Census Bureau, it is estimated that the demand 
for primary total hip arthroplasties will grow by 174 % (to 572,000 procedures), by the year 2030. It 
was also predicted that the demand for total knee arthroplasties would grow by 673 % to 3.48 
million procedures by the year 2030, indicating an increasing demand for improved diagnostics 
methods and treatments (Kurtz et al., 2007). 
2.4.4 Cochlear implant 
The application and administration of antimicrobials are frequently used pre-operatively as a 
prophylactic measure that can prevent the first stage in biofilm formation, that of initial adhesion. 
However, it is clear that there is potential for fungal infections to develop in certain cases, probably 
from adventitious fungal cells in the wound environment. Cristobal et al. presented a case study of 
cochlear hardware implantation in a young girl where oral and topical antibiotics were administered 
one week pre- and post-implantation (Cristobal et al., 2004). Oral cefdinir is a broad-spectrum 
cephalosporin antibacterial agent and topical ofloxacin is a broad-spectrum fluoroquinolone both of 
which are effective against Gram negative and positive bacteria. Four weeks post-implantation, the 
patient developed an infection and fluid sampling showed no bacterial cultures, only cultures of 
Candida spp. These results were dismissed as laboratory contamination and the patient was 
dismissed with a short course of oral amoxicillin. After a further two weeks, the patient presented 
with further signs of infection which was confirmed to be C. albicans, and the cochlear implant had 
to be removed. Analysis of the explanted device showed a mature biofilm of C. albicans covering the 
device. This case shows that antibacterial therapies were effective in clearing bacterial infections. 
However, it could be speculated that this may have provided increased opportunity for C. albicans 
(not affected by these antibacterial agents) to colonize the medical device surface and proliferate. 
This line of thought underscores the importance of anti-infective coating strategies that are targeted 
towards eliminating both bacterial and fungal pathogens. 
3.0 Materials science approaches 
Clinical cases for long-dwelling implantable materials, as well as the difficulties of treating 
established biofilms, show the advantage (or necessity) for medical devices to possess an ability to 
prevent colonization by microbial pathogens. Broadly speaking, materials science strategies can be 
categorized into releasing and non-releasing types. A critical discussion of these approaches and 
their potential advantages and disadvantages have been recently given (Coad et al., 2016). With 
antibacterial surfaces, several reviews have broadly captured the state-of-the-art (Campoccia et al., 
2013; Tiller, 2011; Vasilev et al., 2009). However, in these reviews, antifungal surface coatings have 
been either a minor point or not considered at all. We summarized strategies for antifungal surface 
coatings of the non-release type previously (Coad et al., 2014). The sections below provide an 
opportunity to update this review in the specific context of medical devices and to further expand it 
by also reviewing releasing strategies.  
3.1 Drug releasing strategies  
3.1.1 Release from bulk 
Placing antifungal drugs directly into or onto the material of the medical device is a 
straightforward method of modifying how the surface of the material will interact with microbes 
(Figure 2). However, the material and drugs themselves must be suitable for this approach, 
ultimately limiting the number of drug-material combinations possible.  
 
Figure 2. Materials that release bioactive compounds. Medical device materials with imbibed 
antifungal agents, either in the bulk or in a surface coating, are released by diffusion. The kinetics of 
release and diffusion of the compounds affect their antimicrobial performance.  
 
Using a proprietary aromatic polyurethane (Pellethane) for medical catheters, Schierholz 
and co-workers loaded a combination of the antibiotic rifampicin and antifungal miconazole into the 
bulk of the material via a diffusion-controlled mechanism (Schierholz et al., 2000). Out-diffusion then 
released these compounds into biological solutions; kinetic measurements were made up to 21 days. 
The modified polyurethane surfaces were challenged with clinical isolates, among them three strains 
of C. albicans, although the focus of that work was on bacteria. The zone of inhibition was larger for 
all bacterial and fungal pathogens than for the “gold-standard” catheters coated with chlorhexidine 
and silver sulphadiazine. More importantly, the activity did not diminish after sterilization with 
ethylene oxide and materials retained 90 % of the drug loading after 12 months of storage under 
ambient air. The last point raises an aspect which is often not taken into account: sterilization and 
storage conditions of medical devices can potentially negate the viability of many approaches 
documented in the literature. This highlights an essential point to address if coatings are to proceed 
to human application.  
Braem et al. designed a mesoporous diffusion barrier in the form of silicon oxide for 
controlled drug release from a porous titanium implant (Braem et al., 2015). The porous titanium 
membranes were fouled with foetal bovine serum and the broad-spectrum anti-biofilm molecule 
toremifene was successfully released with a delay of two days without an initial burst in 
concentration. This approach resulted in a 70 % metabolic reduction of C. albicans in RPMI media. 
The study demonstrates that engineering approaches, under-represented in the literature, can also 
lead to more controlled and sustained drug release.  
Apart from pharmaceutical antifungal drugs that can be released from a material, 
halogenated materials have also been shown to be highly efficient at eliminating pathogens. Sun and 
co-workers attached the N-halamine precursor 5,5-dimethylhydantoin (DMH) via an isocyanate 
coupling agent to a polyurethane, followed by halogenating the DMH to the corresponding N-
halamine using a 10 % aqueous sodium hypochlorite solution (bleach) (Sun et al., 2012). The 
resulting material proved to be highly biocidal and fast-acting (log 4 reduction of C. albicans within 
60 minutes of contact time). Additionally, this modified polyurethane could be quenched using 
aqueous thiosulfate solution, recharged after use again with bleach, and retained more than 91 % of 
the initial chlorine concentration after six months of storage. Analogously, Jie and co-workers used 
aqueous potassium iodide to prepare polyurethane-iodine complexes, which caused complete 
eradication of C. albicans and Aspergillus. niger after two or twenty minutes, respectively (Jie Luo et 
al., 2010). Further testing using animal models to date have not been conducted, as free halogens, 
hypochlorites and N-halamines are known to be indiscriminately cytotoxic (Gernhardt et al., 2004). 
However, there are applications, such as urinary catheters, that have minimal contact with human 
cells and thus such biocidal coatings could potentially have merit.  
3.1.2 Release from thin film coatings 
Thin film coatings provide an opportunity to store or associate antifungal compounds in a 
material extraneous to the medical device surface itself. Thus, they provide the ability to modify a 
wider range of devices. Furthermore, this technique allows for the use of more “exotic” 
combinations of polymers for building the coating, and antifungal molecules for in-diffusion (such as 
peptides, polysaccharides or synthetic polymers and analogues). Some compounds cannot be 
delivered orally or systemically and may be less likely to induce resistance in the microorganism 
when administered via local release from a coating on a biomedical device.  
A system of physisorbed thin film coatings (alternating polyelectrolyte layers) was used to 
load a synthetic antifungal beta-peptide, as documented in three publications by Raman, Karlsson 
and co-workers. For their purpose, an initial layer of polyethyleneimine, polystryenesulfonate and 
polyallylamine was deposited onto either glass or silicon substrates (Karlsson et al., 2010). This step 
was followed by alternating layer deposition of poly-L-lysine (PLL) and poly-L-glutamic acid (PGA); 
resulting in layers of up to 800 nm in thickness, which were then in-diffused with a synthetic 
antifungal beta-peptide that was fluorescently tagged with a coumarin unit. This coumarin unit 
enabled quantification of the release kinetics of the beta-peptide via fluorescence over a time frame 
of 400 h. In the next step, the coatings were challenged with C. albicans in RPMI media and found to 
deliver a reduction in the viability of the yeast after two hours, with further reduction in metabolic 
activity observed after seven hours.  
Similarly, other substrates were explored, such as polyethylene catheters which were coated 
with the layer-by-layer technique using PLL and PGA (Raman et al., 2014). Using the same antifungal 
beta-peptide, activity was observed against C. albicans in RPMI media spiked with foetal bovine 
serum, which is a model for biofouling by blood proteins that can negate activity.  
Subsequently, polyethylene catheter tubes were explored using a different layer-by-layer 
coating method using either poly-L-lysine and poly-L-glutamic acid or chitosan (CH) and hyaluronic 
acid (HA); followed by beta-peptide loading (Raman et al., 2016a). The CH/HA layers had almost 
double the loading capacity of the PLL/PGA films and exhibited weak antifungal activity against C. 
albicans without the drug. Finally, the coatings were challenged in a 48 hour in vivo infectious 
central venous catheter rat model, using C. albicans where the coatings showed less robust biofilm 
formation (Raman et al., 2016b).  
A different, “release upon stimuli”, layer-by-layer approach was used by Cado and co-
workers to immobilize the modified antimicrobial peptide cateslytin via a cysteine residue into a 
matrix of HA and CH (Cado et al., 2013). The covalently-bound antimicrobial peptide was intended to 
be released only if pathogen-secreted enzymes (hyaluronidases) degraded the linkage and thus 
released the active drug. In vitro results demonstrated that C. albicans growth was effectively 
inhibited within one hour and the organism completely killed within 24 hours.  
The PLL/PGA multilayer approach was used by Etienne et al. to embed the antifungal 
peptide CGA47-66. This coating exhibited moderate efficacy in vitro against C. albicans, but gave 
more encouraging results in an in vivo oral cavity rat model, showing almost no trace of C. albicans 
under microscopic exanimation (Etienne et al., 2005). Enumeration of viable organisms would have 
been a useful study to quantify the efficacy of the antifungal treatment. 
A radically different approach was used by Manna and co-workers by combining the non-
adherent qualities of slippery liquid-infused porous surfaces (SLIPS) with the biocidal action of a 
fungicide (Manna et al., 2016). For their purpose, silicone oil, which was used to generate the 
slippery liquid interface, was infused with triclosan. Due to the matching hydrophobic character 
between the silicone oil and triclosan, out-diffusion of the fungicide was considerably slowed. Three 
weeks were required to release one-third of the antifungal agent, and a total of 120 days to release 
a cumulative 45 % of the total triclosan loading. This duration of release is much longer than the few 
days obtained with most systems and could assist in avoiding infections during slow wound healing, 
such as in elderly patients. Antifungal testing against C. albicans showed negligible fungal adhesion 
and growth on the surface, and release of triclosan killed planktonic cells. Thus, “dual-action” 
surface coatings not only prevented cellular adhesion and biofilm formation on the surface but also 
reduced pathogens in the surrounding fluids. Reduced cellular adhesion was, however, also 
observed for mammalian cells, which might limit the application to medical devices where tissue 
integration is not important.  
Drug-releasing biomaterials enable delivery of drugs that are otherwise inefficient or even 
impossible to deliver systemically. Anidulafungin, an approved antifungal drug, is one of those drugs, 
but its hydrophobic nature requires intravenous administration. For this reason, Gharbi et al. used 
the hydrophobic inner cavity of cyclodextrins (CDs) to generate stable complexes with anidulafungin 
or the terpene thymol (Gharbi et al., 2012). This approach improved the water solubility of 
anidulafungin by a factor of almost 3500 compared to the bare drug. Loaded CDs were then 
immobilized onto gold surfaces via amide coupling to thiol immobilized tethers, yielding antifungal 
surfaces toward C. albicans that were rechargeable after use. Additionally, the authors speculated 
that the anidulafungin-loaded CDs prevented fungal adhesion whereas thymol-loaded CDs were 
antifungal by killing. However, additional microbiological testing, besides fluorescent microscopy, 
was not undertaken. 
A simpler, yet remarkably efficient, approach was taken by Darouiche and co-workers in 
three separate publications where titanium cylinders were coated by dipping them into a mixture of 
chlorhexidine and chloroxylenol via an undisclosed proprietary technique (Darouiche et al., 1998). 
This step was followed by a zone-of-inhibition test against C. albicans after two, four, six and eight 
weeks of incubation in human serum. Surprisingly, neither the size of the zone of inhibition, nor the 
quantity of the antiseptics appeared to change dramatically over the surveyed time course.  
In a follow-up study, silicone catheters were impregnated via the same method with the 
same antiseptics, sterilized using ethylene oxide, infected with either C. albicans or C. krusei, and 
placed percutaneously into rabbits (Darouiche et al., 2006). This method resulted in a lower number 
of devices becoming infected (50 % instead of 100 % in case of the untreated control) for both 
Candida spp. and a reduction of retrieved CFU from the implant by a factor of 20 or more.  
The final paper in that series involved the dip coating of urinary catheters with chloroxylenol 
and thymol, gas sterilization, and incubation in synthetic urine in vitro. Zone of inhibition tests 
against various pathogens including C. albicans were performed at different intervals for up to two 
weeks (Mansouri and Darouiche, 2008). Again, clinical relevance was evident in the demonstration 
of efficacy after sterilization. 
Finally, drug delivery of antifungals was facilitated by using a biodegradable polymer, 
polyglycolic acid, formed as injection-moulded microneedles. The microneedles were modified by 
ink-jet coating with a water-soluble drug release layer, into which either itraconazole or voriconazole 
was deposited. The focus was primarily on the fabrication of the microneedles, their coating and 
their ability to penetrate porcine skin in vitro. Yet, a simple diffusion inhibition assay revealed 
activity against C. albicans; without studying the release kinetics in detail (Boehm et al., 2015; 
Boehm et al., 2016). 
3.1.3 Release from hydrogels 
In the wider drug release literature, release from hydrogel polymers is a popular approach. 
Here we discuss an illustrative example using an antifungal drug. Amphotericin B is a highly potent 
antifungal compound but it has human cell toxicity and poor water solubility (Scheld et al., 2014). To 
deliver amphotericin B from a surface coating matrix, dextran-based hydrogels (labelled Amphogel) 
were prepared by Zumbuehl et al. via a simple swelling and loading procedure (Zumbuehl et al., 
2007). Releasing hydrogels proved to be highly antifungal against C. albicans (100 % kill rate within 
two hours) and persistent (up to 53 days of repetition). Interestingly, the fungal growth in the 
supernatant was not affected, suggesting that the hydrophobic drug does not diffuse out into the 
media, at least not to a concentration exceeding the minimum inhibitory concentration (MIC). This 
probably results from its low water solubility, with the killing occurring upon contact with drug 
molecules localized on the hydrogel surface. This may be advantageous for cytotoxic drugs such as 
amphotericin B, but does not address the problem of pathogenic spread into the surrounding tissue, 
which needs to be combatted via diffusing drug molecules. In vivo testing in mice over a period of 
three days yielded a log 6 reduction of C. albicans and no presence of host cells in the Amphogel. 
Similar to other approaches previously discussed, this technology offers a promising route for 
applications where host infiltration is not desired. Unfortunately, the fabrication method used in 
that study does not address the issue as to how the Amphogel could be coated readily onto a 
medical device surface.  
3.1.4 Release from grafted polymers 
Compared to thin-film layered coatings and hydrogels, approaches that use surface-grafted 
polymer layers as the storage matrix for antifungal drugs offer some advantages (schematically 
illustrated in Figure 3). They are typically thicker than thin film coatings, which increases the 
potential antifungal reservoir, and they are covalently attached to the substrate. Advances in 
polymer grafting technologies now seek to release drugs from materials in a more controlled 
manner, and also incorporating means for obtaining release triggered by external stimuli.  
 
Figure 3. Schematic of grafted polymer chains (or polymer brushes) that serve as a storage matrix for 
the loading of antifungal compounds into the surface layer. Once implanted, desorption of the 
compounds results in diffusion away from the matrix into the fluids surrounding the device. 
A ‘release on demand’ coating was developed by Segura and co-workers by gamma 
irradiation of silicone rubber, followed by the exposure to glycidyl methacrylate to form a grafted 
polymer layer up to 20.9 % by weight (Segura et al., 2014). The reactive epoxy groups of the grafted 
polymer were then used to covalently bind ergosterol, a sterol essential in fungal cell biology. The 
grafted ergosterol was then used to reversibly associate with the antifungal drugs natamycin and 
nystatin, which have an affinity for ergosterol, as well as the azole-class drug miconazole. As 
expected, there was selective uptake, into the grafted layer, of natamycin and nystatin, whereas 
nonselective in-diffusion was observed with miconazole, which does not specifically associate with 
ergosterol. Liposomes mimicking mammalian and fungal cell membranes (containing cholesterol or 
ergosterol, respectively) caused different rates of release and endpoint concentrations, with faster 
release upon contact with ergosterol-containing liposomes. Unfortunately, these encouraging results 
only translated partially in fungal testing against C. albicans and A. fumigatus, as natamycin-loaded 
samples did not cause any pathogen inhibition in a contact assay. In contrast, nystatin-loaded 
surfaces did inhibit A. fumigatus and caused C. albicans to remain in its less virulent yeast 
morphology. However, less than a log 2 reduction in CFU/cm2 of C. albicans was achieved. These 
results demonstrate that even stimulated drug release does not necessarily translate into effective 
inhibition of fungal pathogens when required.  
A similar, but non-selective, approach was undertaken by Sun et al. A layer of the 
biocompatible polymer poly(N-vinyl-2-pyrrolidinone) (PNVP) was grafted onto plasma-activated 
polymethylmethacrylate (PMMA) denture resins, reaching grafting densities close to 8 % by weight 
(Sun et al., 2013). The grafted PNVP was then infused with either miconazole or the disinfectant 
chlorhexidine, releasing the former for up to 60 days or the latter for 14 days to reach solution 
concentrations above the MIC. Samples challenged with C. albicans caused a marked reduction in 
metabolic activity over the same period of time and no fungal adhesion was observed by 
microscopy. Furthermore, the PNVP coatings could be either “quenched” by immersion into PNVP 
aqueous solution or “recharged” with the antifungal drug. Lastly, lack of cytotoxicity against 3T3 
mouse fibroblasts was confirmed; however, it should be considered that the antifungal tests were 
done in PBS media, whereas the cytotoxicity tests were conducted in DMEM media with added 
serum. This difference raises the question as to what role the media and sera, into which the 
antifungal drug is being released, play, and how they affect the release kinetics and activity. Ideally, 
antifungal and cytotoxicity tests should be done in the same medium, to avoid artefacts due to 
association between drug molecules and components of one or the other medium. Unfortunately, to 
date, there are no publications comparing the effect of media on the release kinetics and potency of 
antifungal drugs.  
3.1.5 Silver 
Silver has been of considerable interest for its ability to ward off diseases even prior to the 
emergence of germ theory and modern medicine. Hence, it is not surprising that its qualities have 
also been used in the modern setting of antimicrobial coatings (Marambio-Jones and Hoek, 2010). 
Silver has a recognized antibacterial and antifungal effect and has therefore received attention for 
incorporation into commercial medical devices. However, in clinical studies, the overall benefit has 
not been clearly established and considerable discrepancies exist in findings reported in the 
literature (Brennan et al., 2015; Schierholz et al., 1998). More recently, evidence has emerged 
indicating cytotoxicity of silver (ions), as well as inactivation of silver ions in protein-containing 
media (AshaRani et al., 2009; Marambio-Jones and Hoek, 2010; Xiu et al., 2012). However, research 
into the use of silver as a surface-active antimicrobial remains a highly active research area, though 
antifungal applications have received far less attention than antibacterial usage. In this context, we 
now highlight a few examples of antifungal surface coatings based on silver. 
A straightforward coating approach, by Roe and co-workers, involved the reduction of silver 
nitrate by tetramethylenediamine in the presence of Tween 20 as a surfactant and deposition onto 
catheters (Roe et al., 2008). As expected, the growth of C. albicans and other pathogens on silver-
coated catheters was inhibited in vitro. The same coatings were also produced using the radioactive 
isotope 110 of silver and implanted subcutaneously into the dorsum of mice for ten days. Results 
revealed that almost no silver was excreted by urine, yet up to 8 % of the total implanted silver was 
lost through faeces, mostly within the first four days. A further 3 % was recovered from the tissue 
surrounding the implant site and almost no silver was detected in the ribcage or other organs. 
Hence, the authors suggested that the silver would be unlikely to cause systemic toxicity; though 
there was no mention of effects on adjacent, exposed tissue. Additionally, the authors speculated 
that there could be the possibility for the emergence of pathogens with a higher resistance to silver 
due to increased effectiveness of efflux pumps.  
A more targeted approach was investigated by Prucek et al., who synthesized magnetic 
binary nanocomposites of silver and iron oxide (Prucek et al., 2011). The aim of these magnetic 
nanocomposites was to direct the antimicrobial particles via a magnetic field to the target area, and 
to allow for the facile collection of the silver particles at the end of the treatment. The 
nanocomposites proved to be highly antifungal against C. albicans, C. tropicalis and C. parapsilosis in 
solution. However, the authors noted that the nanocomposites were cytotoxic towards NIH3T3 cells; 
this is consistent with the many reports about silver’s cytotoxicity.  
The antimicrobial activity of silver was also investigated in combination with nitric oxide 
(NO) in the work of Privett and co-workers. NO has a demonstrated antimicrobial effect, also 
capable of mitigating the proliferation and adhesion of various microbes including fungi (Brunelli et 
al., 1995; Neufeld and Reynolds, 2016; Ullmann et al., 2004). For this purpose, amine containing 
xerogels were produced on glass slides via siloxane chemistry and then charged with pressurized NO 
to generate diazeniumdiolate groups that are known to release again the short-lived NO radical 
molecule (Privett et al., 2010). The xerogels were challenged with C. albicans under flow conditions, 
which revealed a decrease (20-35 %) in fungal adhesion that was more pronounced at lower 
flowrates. This result led the authors to suggest that NO alone, while reducing adhesion, may not be 
sufficient for preventing fungal colonization. For this purpose, silver suldaziazine was added in sub-
fungicidal concentration to the fungal solution and the drug appeared to work synergistically against 
fungal adhesion with the NO releasing xerogels. 
3.2 Non-release coatings 
In this section, two strategies are summarized that could prevent colonization of medical 
devices by pathogenic fungi. First, we discuss barrier-type coatings that physically disrupt the 
adhesion process. Second are surfaces or coatings that contain antifungal molecules. 
3.2.1 Anti-fouling/anti-adhesive coatings 
Anti-fouling/anti-adhesive coatings work by reducing the surface affinity of biomolecules to 
preferentially adsorb to surfaces (Figure 4). These can be structurally quite simple coatings, such as 
hydrogels, or involve more complex architectures, such as polymer brushes. In the biomaterials 
literature the ability of hydrogel coatings, of various chemical compositions, to reduce or altogether 
prevent attachment of mammalian cells is well known. A number of studies have also investigated 
the use of such “antifouling” or “anti-adhesive” coatings to prevent attachment and biofilm 
formation by fungal organisms. For example, Roosjen et al. covalently-attached poly(ethylene oxide) 
polymers to glass surfaces, resulting in a polymer brush layer. This low-fouling polymer layer was 
effective in causing a 70 % reduction of growth of C. albicans and C. tropicalis after four hours 
compared with the uncoated glass surface. Interestingly, the observed reduction for Gram-positive 
and Gram-negative bacteria was generally higher, and it was reasoned that the smaller size of the 
bacteria was the cause (Roosjen et al., 2003). In subsequent work, polyacrylamide was densely 
grafted from a model substrate using SI-ATRP. On these brushes, the adhesion of C. albicans was 
decreased by 70 % (compared to the uncoated surface). However, the strength of adhesion was 
found to be very weak, not only on the brush surface but also on the control (silicone) surface where 
more than 99 % of the pathogen cells could be removed by passing an air bubble over the surface 
(Roosjen et al., 2006).  
 
Figure 4. Anti-fouling (anti-adhesive) coatings repel adsorbing biomolecules. This strategy aims to 
prevent the first stage in biofilm formation on the device (adhesion) without necessarily combatting 
the pathogens themselves. Such coatings on medical devices, however, do not address how to 
encourage integration with mammalian tissues. 
These two studies, and others, show that barrier coatings of polymer brushes are effective 
at reducing yeast adherence by more than two-thirds. This reduction is, however, less than observed 
for mammalian cells. Clinical utility of such coatings would depend upon the implantation site of the 
device, and whether flow forces surrounding the surface coating could provide forces sufficient to 
remove weakly adhered organisms. The lumen of urinary catheters would seem a possibility. 
Furthermore, a question remains about viable, yet non-device adhered organisms and whether 
these could then cause infection in surrounding tissues. Moreover, given the fast replication rates of 
micro-organisms, a reduction of 70 % amounts to a rather short-lived reduction; three orders of 
magnitude or more are considered desirable. 
A study conducted in 2010 explored how hydrophobic interactions impact adherence of 
Candida spp. to acrylic surfaces that compose denture materials, aiming to reduce microbial biofilm 
formation and denture-induced stomatitis (Yoshijima et al., 2010). For this purpose, hydrophilic 
substrates were created by coating acrylic plates with carrageenan and hydrocolloid, and challenged 
with 27 isolates from Candida spp. (including C. albicans, C. parapsilosis, and C. glabrata). 
Additionally, a hydrocarbon adherence assay was used to measure cell surface hydrophobicity, 
which involved measuring the turbidity of the aqueous fungal cell suspension. The authors 
concluded that coating acrylic plates with hydrophilic materials decreased the adherence of 
hydrophobic hyphal Candida spp., without affecting the adherence of non-hydrophobic Candida spp. 
cells. 
3.2.2 Contact killing 
Using well-known chemical reactions, many antifungal drugs can, in principle, be covalently 
attached onto suitable complementary chemical groups on medical device surfaces. Such covalent 
bioconjugation immobilizes the drug molecules permanently on the device surface (Figure 5). The 
antifungal agents are thus incapable of leaching into solution (and adjacent tissues) which offers 
both advantages and disadvantages. It is important to consider interfacial phenomena between the 
coating and cells. On the one hand, this approach presents attaching pathogens with a locally high 
concentration of the antifungal agent on the surface; on the other hand, the immobilized drug 
molecules do not act upon fungal colonization of the surrounding tissue that is not in immediate 
contact with the coating. Furthermore, the antifungal agents of choice must target an extracellular 
component of the pathogen; intracellular targets are obviously not amenable to surface-bound drug 
molecules. In the case of fungi, this strategy often targets either the β-D-glucan synthase enzyme 
(using echinocandin-class drugs), ergosterol (using polyenes), or the lipid bilayer itself (using cationic 
polymers or antimicrobial peptides). Furthermore, immobilization of a compound on a surface 
inherently leads to a restriction of its rotational freedom.  
 
Figure 5. Schematic of materials with surface-bound bioactive compounds. Medical device materials 
with covalently attached biomolecules could act as “contact-killing” surfaces upon exposure to 
fungal pathogens. For this to be true, it is important to analytically verify that prepared surfaces do 
not leach bioactives, otherwise, the mechanism of action could be unclear and confused with 
releasing materials. 
 
In the interest of both scientific rigour and quality control in manufacture, sensitive surface 
analysis methods must be employed to determine if the compound indeed remains covalently 
attached to the medical device surface; otherwise, an antifungal effect may be observed, but could 
be due to possible release or desorption of adsorbed compounds (Coad et al., 2016); such 
unintended release would require additional in vivo testing of toxicity to adjacent tissue and possible 
effects on organs. 
3.2.2.1 Grafted antifungals 
Regulated antifungal drugs that are approved for clinical use are a promising class of 
antimicrobial compounds because they have a well-known mechanism of action and known toxicity 
limits. Compared with antibacterial drugs, there have been very few reports of surface-grafted 
antifungal drugs since the time of our review on the topic of surface-immobilized antifungals (Coad 
et al., 2014). 
Coad et al. demonstrated irreversible attachment of the antifungal drug caspofungin using a 
substrate-independent coating technique which could be applicable to different bulk biomaterials as 
an essentially two-dimensional surface coating (Coad et al., 2015; Griesser et al., 2015; Michl et al., 
2017a). It was shown that using only water or buffer washes was not sufficient in removing the 
reversibly-bound caspofungin. In fact, after such washes, the majority of the caspofungin (two-
thirds) was available to reversibly desorb. However, SDS washing at 70 ⁰C was shown to be 
necessary for preparing a surface with only covalently attached caspofungin. Covalently-bound 
caspofungin was effective in eliminating C. albicans, C. tropicalis, C. parapsilosis and C. glabrata 
using a contact-killing assay. The surface coating was also found to have no adverse effects on 
attachment and growth of mammalian primary fibroblasts (Griesser et al., 2015). Finally, the killing 
ability of surfaces with attached caspofungin was not diminished even after pre-conditioning the 
surface with adsorbed layers of protein (Michl et al., 2017a). 
Kucharikova et al. examined caspofungin binding to titanium surfaces (Kucharíková et al., 
2015). Biological testing revealed that the caspofungin-treated materials completely prevented 
biofilm formation in vitro and inhibited by 89 % in vivo (rat model). As a potential therapy for bone 
implantation, these surfaces showed very good potential for promoting osseointegration. However, 
the simple method of washing, the reported high surface density of caspofungin (much exceeding 
what one would calculate for a grafted layer), and the SEM images suggest the possibility that at 
least some of the caspofungin molecules present were in the form of physically adsorbed 
multilayers. This raises the question of whether exposure to the surface (contact killing) or exposure 
to released molecules (solution killing) is responsible for the antifungal effect. Such questions would 
be important to investigate for the longevity of implanted devices. 
Another surface coating technique uses the concept of polymer brushes (as described 
above), not as a storage matrix, but as an attachment matrix to extend the reach of covalently-
attached bioactives from the surface (Figure 6). This provides an opportunity to present antifungal 
drugs on polymers that have improved conformational flexibility that may help them interface with 
the fungal cell wall. Also, the supporting polymer brushes can themselves be low-fouling which 
reduces the potential for fungal attachment or surface fouling by biomolecules (see section 3.2.1). 
Michl et al. showed that polymer grafts from 2-hydroxyethylmethacrylate (HEMA) had a substantial 
effect on C. albicans, reducing their surface attachment and preventing formation of hyphae (Michl 
et al., 2017b). However, the yeast-form remained alive on the brush surface. When conjugated with 
caspofungin, greater that log 4 killing was observed. A slight biocidal effect was observed in the 
supernatants above the grafted surface, indicating a proportion of caspofungin had released into 
solution. However, this effect was small compared to cells exposed to the grafted surface suggesting 
the dominant effect of the contact killing mode of action. All of these studies reinforce the 
importance of considering the possible release of antibiotic agents and whether they can be 
classified as contact-killing or through a drug release mechanism (see section 3.1.2). 
 
Figure 6. Schematic of materials with bioactive compounds tethered to polymeric linkers. In this 
strategy, bioactive compounds are covalently attached to polymer chains that extend away from the 
surface of the coating on the medical device. The polymer grafts present the compounds on flexible 
linkers providing a dynamic interface when exposed to fungal pathogens. 
3.2.2.2 Peptides 
Antifungal peptides are a novel class of antimicrobials that are being investigated as anti-
infective surface coatings. Li et al. investigated surface tethered antimicrobial peptides to poly(allyl 
glycidyl ether) polymers grafted from polydimethylsiloxane (PDMS) or urinary catheter substrates (Li 
et al., 2014). These materials were antimicrobial against C. albicans as well as E. coli and S. aureus. 
To rule out non-covalent attachment to the substrate, the non-grafted PDMS material was shown 
not to adsorb the peptides. However, physisorption within the polymer brush was not tested (this 
mechanism could operate for the delivery of antifungals as shown in section 3.1.4). This possibility 
could have been investigated by first quenching the reactive epoxy groups with a small nucleophile 
and then adsorbing the peptides to see if they were subsequently released. Alternatively, biological 
evaluation of the supernatants could have been used to assess the release of any peptides. These 
constructs were found to be non-cytotoxic to smooth muscle cell lines.  
3.2.2.3 Small MW organics 
Lin and co-workers reported on the use of polystyrene which was modified with various 
chlorinated or iodinated amides for antifungal applications (Lin et al., 1996). Importantly, these 
modified polystyrenes were tested for their ability to leach halogens, after sufficient washing cycles. 
Testing against C. albicans and Saccharomyces cerevisiae (S. cerevisiae) revealed that there was no 
zone of inhibition around the modified polystyrene in diffusion tests, yet swift killing (in less than 
one hour) occurred upon contact in solution. This effect was more pronounced for shorter amide 
chains and more so for Iodinated- than for chlorinated-polymers. The biocompatibility and mode of 
action were not reported for these materials.  
Lino and co-workers infused the hydrophobic antifungal amphotericin B into oxidized 
dextran, to improve its water-solubility, and then in turn conjugated to silica nanoparticles with a 
diameter of either 5 nm or 80 nm. Finally, these functionalized nanoparticles were then 
incorporated into a commercial dental resin at 2 % w/w (Lino et al., 2013). Both the particles as well 
as the particle-loaded resin were tested against C. albicans, C. tropicalis, C. parapsilosis, C. glabrata 
and C. krusei. The functionalized 5 nm particles and resins loaded with nanopaticles showed a better 
performance compared to the 80 nm analogues which the authors explain with a higher surface to 
volume ratio. Furthermore, the authors claim that the particles and surfaces are contact-active only 
as decanted media lacked any antifungal activity; hence exploiting the poor water-solubility of 
amphotericin B to confine it locally.  
Plasma polymerization, was used to deposit antifungal coatings in one step using a 
substrate-independent method (Lamont-Friedrich et al., 2016). For this, 1,1,2-trichloroethane was 
plasma deposited onto plastic substrates using previously detailed plasma polymerization methods 
(Griesser, 1989; Michl et al., 2014; Michl et al., 2015; Michl et al., 2016; Vasilev et al., 2011). 
Although non-releasing, low molecular weight chlorine species were present and were biocidal to 
fungal cells at the surface. The antifungal activity was demonstrated against the dimorphic C. 
albicans and non-dimorphic C. glabrata, by suppressing their surface colonization in excess of 24 
hours. Finally, it was concluded that the mechanism of action and activity against other clinically 
significant fungi warrant future investigation. 
3.3 Potential for generating microbial resistance from antifungal biomaterials  
Is it possible that antifungal surfaces and coatings on medical devices that act 
prophylactically could contribute to the problem of antifungal resistance? For example, for releasing 
coatings, does a diminishing antifungal concentration away from the implant establish a sub-
inhibitory concentration thereby inducing resistant populations? To our knowledge there are no 
studies that have looked at this question in the specific case of fungal pathogens. In bacterial 
applications, Campoccia et al. reviewed this scenario in the context of gentamicin releasing bone 
cements and the induction of gentamicin-resistant populations (Campoccia et al., 2010). In vitro and 
clinical data clearly show that the possibility exists. This possibility, however, is dependent on many 
factors, including the nature of the releasing matrix and the concentration of the inoculum, with 
these findings most relevant to orthopaedic implants and formulated as bone cement. Evidently, 
more studies need to be conducted in this area. 
With contact-killing surfaces (non-release), again, no studies have investigated specifically 
the possible induction of antifungal resistance by contact with antimicrobials permanently tethered 
to materials surfaces. For bacteria, there have been arguments put forth based on limited studies. 
Intuitively, surfaces that are incapable of releasing antifungal agents (because they are covalently 
attached) would prevent diffuse concentration gradients and may be more effective in preventing 
acquired resistance. Antoci et al. used covalently attached vancomycin surface coatings for a study 
involving one-month continuous exposure to S. aureus and found no evidence of acquired resistance 
(Antoci et al., 2007). It can be argued that even if a very small proportion of an antifungal agent were 
to become desorbed, hydrolysed, or otherwise released from the surface, the resulting solution 
concentration would likely be several orders of magnitude below the minimum inhibitory 
concentration. In the worst-case scenario of the complete elution of all compound from a surface, 
there might be a total dose of several hundred ng per mL in the surrounding fluids, which could then 
be adsorbed as well as diluted in tissues or otherwise cleared through the circulatory system and the 
immune response. Such complete failures would be unlikely for a regulated implant. Due to the 
growing concern of antifungal drug resistance, however, the possibility of induced resistance needs 
to be assessed experimentally. 
4.0 Challenges in the design of antifungal surface coatings 
4.1 in vitro assays for evaluating antifungal surfaces 
Currently, in vitro assays are limited in their ability to imitate in vivo conditions. Buhmann et 
al. discussed the significance of incorporating clinically relevant conditions when testing anti-
infective surfaces in vitro to assist in predicting in vivo function. The article further suggested that 
the failure of many current anti-infective device coatings may be due to this limitation of in vitro 
tests not providing a realistic test environment. The importance of growth medium, fluid flow, 
intracellular interactions and the material properties including roughness, topography, chemical and 
mechanical properties were all emphasized as having a role. Consideration in designing in vitro 
assays that mimic in vivo conditions will aid in translating more anti-infective surfaces into the 
clinical setting (Buhmann et al., 2016). 
In a letter replying to that paper, Qu and co-workers highlighted appropriate conditions for 
screening anti-infective surfaces in the microplate biofilm assay, and suggested suitable media, 
adhesion and biofilm formation conditions, and solutions to some of the problems associated with 
common device-associated biofilm producing microorganisms. Their letter also highlighted the need 
for co-culture of different bacterial and fungal species in consideration of polymicrobial in vivo 
conditions. The importance of screening anti-infective surfaces in the presence of proteins, using 
media such as foetal bovine serum, was also highlighted (Qu et al., 2017). 
Finally, evaluation of contact-killing antimicrobial surfaces by the use of various standard 
methods can often yield conflicting results. In the case of evaluation of antibacterial surface 
coatings, it was recently shown that the evaluation of the antimicrobial efficacy of a surface coating 
was dependent on the choice of assay (van de Lagemaat et al., 2017). This example illustrates the 
importance of choosing an assay, how the results are interpreted, and the need to use 
complementary testing methods, as discussed below.  
4.1.1 Assay Design 
Multiple key outcomes in designing a microbiological assay to test a surface must be 
considered. The foremost concern should be the number of replicates. Due to the inherent 
variability of microbiological and cellular based assays, it is vital that a minimum of three biological 
replicates and three technical replicates are utilized with appropriate controls present. Replicates 
should be tested against different surface batches, allowing for the rigorous testing of the surface, 
ensuring reproducibility of the in vitro assay is present.  
Outcomes of in vitro studies are dependent on the fungal strain used. Ideally the surfaces 
should be tested with both a typed strain (ATCC –American Typed Culture Collection) and a clinical 
strain. The use of a widely reported strain validates the work amongst peers, while the use of a wild-
type clinical strain demonstrates potential effectiveness of the surface in clinical applications. Fungi 
are known to lose virulence after repetitive sub-cultures in laboratory conditions (Butt et al., 2006). 
Strains lacking particular virulence genes or gene-deleted strains are not suitable to use in initial 
surface testing and are more pertinent to the mechanism of action based experiments, where one 
requires a better understanding of the way the fungal cell and the surface interact. Care must also 
be taken when using drug resistant strains as these strains are phenotypically different compared to 
their wild type counterparts with reduced fitness that can produce a varied response (Ben-Ami et al., 
2011). The other factor that must be considered in strain selection is whether or not the strain can 
produce a biofilm. The difference in results between planktonic and biofilm producing strains may 
significantly impact on the interpretation of a surface’s function.  
4.1.2 Assay selection 
Selecting complementary assays can generate a more complete picture of how well the 
antifungal surface is performing. For a more complete understanding of the effects of an antifungal 
surface, multiple microscopy and quantitative methods are required (Martinez et al., 2010) where 
correlative data should be present. 
 
Figure 7. Schematic steps involved in the microtiter plate biofilm assay of antifungal surface coatings 
against biofilm-forming yeasts (Chandra et al., 2008). Treated coupons are materials with antifungal 
surface coatings applied. These are incubated with fungi where initial attachment to the surface is 
allowed to occur. After biofilm formation, test surfaces are washed and the biofilm is removed by 
sonication/vortexing. Viable colony forming units in solution are appropriately diluted, plated and 
counted. 
 
Chandra et al. reviewed in vitro assay methods for Candida spp., summarising some precise 
methods for biofilm assays and including troubleshooting tips (Chandra et al., 2008). The general 
schematic for this assay is shown in Figure 7. This review further emphasized the need to use 
multiple microscopy methods including fluorescence microscopy, confocal scanning laser microscopy 
(CSLM) and scanning electron microscopy (SEM) to better determine the morphology and 
architecture of the fungal biofilm. Each method adds complementary information. Fluorescence 
microscopy provides whole biofilm images and is limited to a 2D plane of the biofilm; however, this 
method can be useful when investigating adhesion over time on antifungal surfaces. CSLM presents 
an insight into the 3D structure of the biofilm matrix in a low resolution, yet does allow for the 
observation of a hydrated biofilm matrix. While SEM can offer greater information on the surface 
topography, a major limitation is that the SEM preparation dehydration steps can particularly 
degrade the biofilm matrix (Chandra et al., 2008). Live-dead cell staining kits for fluorescent 
microscopy are useful for discriminating yeast cells based on permeability to propidium iodide 
(Figure 8). Older staining methods including crystal violet are limited, due to the stains inability to 
differentiate between live and dead cells and the variation that is seen in the assay (Chandra et al., 
2008).  
 
Figure 8. Live-dead cell assay for visualising cell viability on an antifungal surface coatings. Candida 
albicans was exposed to surfaces and imaged after 180 minutes using live-dead cell staining. A) On a 
control surface showing live cells (green) with normal pseudohyphal development. B) On a 
caspofungin-grafted surface coating, showing dead cells (red), cellular debris and no hyphal 
development. Magnification 40 X; scale bar 20 µm. Unpublished data from the Coad and Griesser 
research group. Methods for manufacture of caspofungin-grafted surface coatings were previously 
described (Coad et al., 2015). 
The XTT assay is a commonly used colorimetric tetrazolium salt-based assay when used 
alone to determine surface activity and fungal metabolism has a number of limitations. Thus use of 
this assay must be considered carefully if it is to be deemed quantitative. Considerations include the 
lack of relationship linearity between organism number and colorimetric signal. Also, a variance in 
tetrazolium metabolism rates occurs in different fungal strains and species. Some strains retain a 
significant amount of the XTT product formazan intracellularly, and formazan is not water soluble as 
previously documented (Roehm et al., 1991). Furthermore, the differential release of formazan from 
biofilm and planktonic cells must also be considered. Finally, the XTT assay has not demonstrated a 
linear relationship between the concentration of XTT used and the colorimetric signal produced. Due 
to these assay limitations an appropriate standard must be present to validate the concentration of 
tetrazolium used and is not suitable for the comparison of different fungal strains (Kuhn et al., 2003). 
This assay is a good indicator of cellular activity; however, it must be conducted in conjunction with 
other assays to determine antifungal surface activity and care must be taken when the XTT assay is 
considered quantitatively.  
An alternative quantitative method that can be utilized to examine antifungal surfaces is the 
microtiter plate biofilm assay (Coenye and Nelis, 2010) where the detailed methodology has been 
described previously (Chandra et al., 2008; Michl et al., 2017a; Michl et al., 2017b). This assay 
provides a quantitative measurement of the colony forming units and the biofilm formation on 
antifungal and control surfaces. Care must be taken in ensuring the adhesion and growth times are 
adjusted according to the species being tested. This method is limited to yeast-based fungi and 
bacteria but may possibly also be useful in quantitating polymicrobial biofilms with the use of 
appropriate controls and microorganism selection.  
Nutrient flow based assays utilising a modified Robbins device have also been reported to 
test the activity of anti-Candida biofilms (De Prijck et al., 2010), with flow displacement and biofilm 
model systems reviewed previously for Candida species and bacteria (Coenye and Nelis, 2010). 
Care must also be taken when selecting and designing an assay. Considerations include the 
clinical application for which the antifungal surface is aimed and the type of microbes which colonize 
this environment, while keeping in mind the type of surface and the appropriateness of the trial 
design (Buhmann et al., 2016). Fouling substances such as proteins or cellular debris must also be 
considered and an investigation into the effects of these factors and their activity need to be 
undertaken. The role of the immune system should also be considered in its interaction with the 
surface of the biomaterial or biomedical device. Awareness of the limitations of the in vitro assay is 
vital to the success of the investigations. The effects of nutrient availability, flow, pH, time, and shear 
forces have all been noted for their effects on cell adhesion and biofilm growth (Buhmann et al., 
2016; Soll and Daniels, 2016). These variables should mimic conditions most similar to the 
biological/physiological environment the material surface will encounter in its intended application.  
4.1.3 Cell culture assays 
Care must be taken when making statements about the growth of mammalian cells on the 
surface of antimicrobial materials and the cytotoxicity of the surface to mammalian cells. Choice of 
cells is vital to soundly understand the toxicity of the surface. Selecting primary cells corresponding 
to cellular types that will likely be in contact with the device at its intended implantation site is best. 
Transformed or continuous cell lines are not considered ‘normal’ cells and often have differing 
phenotypes and physiology compared to primary cells and this must also be considered.  
Hemocompatibility testing of a surface is also important for biomaterials intended to be 
exposed to blood to test for platelet activation, adhesion, aggregation or haemolysis of red blood 
cells (Adams et al., 2003; Hilpert et al., 2009; Kazemzadeh-Narbat et al., 2013). The use of 
erythrocytes to test cytotoxicity does not translate to other metabolically active cell types due to the 
haematopoietic origin of these cells, lack of a nucleus, no coding DNA, lack of redox energy, short 
lifespan and their inability to self-divide. For these reasons erythrocytes are not suitable for pre-
implantation studies alone and a primary cell type from the local area of implantation should be 
considered.   
4.2 In vivo evaluation: critical issues 
A review by Soll and Daniels has extensively reviewed in vivo models that have been used to 
study the formation of Candida spp. biofilms on biomedical devices and model materials. That 
review describes, in detail, intravenous catheter models, urinary catheter models, denture models 
and indwelling subcutaneous pouch models (Soll and Daniels, 2016).  
In vivo catheter models are common for testing antifungal strategies with biomedical 
devices (Martinez et al., 2010). Various small animal central venous catheter (CVC) animal models 
have been developed, including rat (Andes et al., 2004), rabbit (Schinabeck et al., 2004) and mouse 
(Lazzell et al., 2009), which have shown promise for understanding biofilm formation on CVC devices 
and possible treatments (Coenye and Nelis, 2010). The CVC model is limited by the ability to coat the 
internal surface of the catheter tubing where the Candida spp. is administered. However, studies 
have shown some success with pre-inoculation of a treated catheter in a rat in vivo model (Martinez 
et al., 2010). Tail vein administration of Candida spp. serves as a method to establish a disseminated 
Candida spp. infection and can be useful to monitor planktonic cell levels and systemic antifungal 
treatment (Nett et al., 2007; Nett et al., 2011). 
An alternative in vivo model that may be more appropriate to testing surfaces is the rat 
indwelling urinary catheter model. This model successfully demonstrated the proliferation of C. 
albicans on the surface of the device, including the development of adherent yeast and filamentous 
cells in the extracellular matrix of the biofilm (Nett, 2014). This model utilized quantitative methods 
to monitor the infection within the bladder and the biofilm formation on the external surface of the 
catheter and SEM to study the biofilm matrix. The authors detail the problems associated with using 
silicone catheters for SEM assessment, where the biofilm can peel away from the surface during the 
dehydration step (Nett, 2014), such an artefact was not seen previously when polyethylene was 
used (Andes et al., 2004; Wang and Fries, 2011). A urinary catheter model would be suitable to test 
impregnated catheters or catheters with surface modification. The model also takes into account the 
effects of proteins, immune system factors, and cell adherence on the material surface. An 
ascending candiduria catheter mouse model has also been established (Wang and Fries, 2011). 
Subcutaneous models have also been developed. Such models pre-inoculate the implant 
with microbes to mimic a typical surgical contamination load on the implant. If the surface is pre-
inoculated using 60-90 minutes of adhesion time, this protocol is considered to mimic the conditions 
that the implant encounters when contaminated on insertion. This method models the ability of the 
surface to withstand microbial loads in an environment under physiological conditions (Coenye and 
Nelis, 2010). A subcutaneous pocket model in rats has also been developed using pre-inoculated 
catheter segments implanted in the subcutis of the rat (Řičicová et al., 2010). 
Oral candidiasis is predominantly caused by denture-associated stomatitis, whereby Candida 
spp. biofilms form on the prosthetic denture surface. A rat denture stomatitis model was developed 
which imitates Candida spp. biofilm formation and the histology often seen in human cases. One 
limitation encountered in this model is the size of the device. A higher burden of enteric microbes is 
present in the rat compared to humans due to their natural cleaning behaviours and therefore 
appropriate antimicrobials should be administered prior to denture (Nett et al., 2011). 
4.3 Surface analysis 
Surface analysis is imperative for the characterization of biomaterials. Several prominent 
reviews describe the various analytical techniques available, in the context of medical implant 
materials (Born et al., 1998; Kingshott et al., 2011; Merrett et al., 2002). For antifungal biomaterials 
(or antimicrobial biomaterials in general) chemical and physical characterization of the surfaces of 
implantable materials provides the first understanding of the way in which these materials 
potentially act with biological systems. For example, for releasing coatings, at the very least, surface 
analysis can confirm the presence and provide an estimate of the active antimicrobial compound, 
and details of its release kinetics. These will be important for regulatory bodies in the approval 
process for novel medical devices. 
Detailed surface analysis will also provide new insights into cell/surface interactions and 
could potentially reveal novel mechanisms of action. This approach is illustrated well by the case of 
contact killing surfaces. If it can be analytically verified that surface-attached antifungals are 
incapable of being released or desorbed from surfaces, then it can be proved that active antifungal 
compounds can act through novel surface interactions while conformationally constrained. This 
represents a different understanding of a drug’s pharmacokinetic profile and such an arrangement 
can be thought of as new surface-active formulations of a drug. Perhaps immobilising “failed” drugs 
to surfaces (i.e. drugs not approved due to evidence for accumulation in kidneys and liver) might be 
one way of finding new uses for unused, yet highly effective antimicrobials, thus enlisting old 
compounds for new purposes in the fight against device-related infections. Such devices, of course, 
would need testing to prove their efficacy and safety. 
4.4 Selectivity 
Selectivity, in the context of antimicrobials, refers to the efficacy of an antimicrobial agent to 
inhibit a pathogenic organism while providing minimal adverse effects on cells and tissue of the host. 
Perfectly selective antimicrobial agents would interact via a cellular pathway that is unique to the 
pathogen and thus absent in host cells. Of course, perfect selectivity is not achievable because 
human cells and microbes have shared evolutionary history and, therefore, possess a number of 
conserved biological structures, such as a cell membrane. However, subtleties are important here 
and phospholipid membranes provide a good example of the differences between fungi and 
bacteria. The cell membranes of bacteria are different from those of eukaryotic organisms. In 
bacteria, acidic phospholipids (bearing partial negative charge) tend to be presented on the outer 
and inner (cytosol) leaflets of the cell membrane. In contrast, eukaryotic organisms (including fungi 
and mammalian cells) have active metabolic processes that sequester these phospholipids on the 
inner leaflet of the cell membrane (Cerbón and Calderón, 1995; Devaux, 1991). The result is that 
some bacterial membranes tend to possess more negative character on their outer cell membrane. 
This difference explains the selectivity of cationic compounds such as quaternary ammonium ions, 
peptides, and polysaccharides towards selective killing bacterial cells (over mammalian cells). In 
contrast, because of their structural similarity, cell membrane arguments alone should not be used 
to explain how cationic agents might selectively kill fungal pathogens while not harming mammalian 
cells in so-called “broad spectrum” antimicrobials (Engler et al., 2012; Li et al., 2011). Instead, the 
particular structural biology of the fungal cell wall should not be overlooked (Gow et al., 2017). As 
mentioned above (section 3.2.2.1), contact-killing surfaces bearing antifungal agents that target the 
fungal cell wall, that also possess an acceptable low toxicity in human applications (as approved by 
regulatory bodies) could be promising in the development of antifungal medical devices.  
4.5 Toxicity 
The number of approved antifungal drugs and therapies has certainly been limited severely 
by their toxicity (Brown et al., 2012); the number of antifungal drugs is considerably less than that of 
antibacterial drugs. This is mainly a result of the narrow window of selectivity, as mentioned above. 
For disinfectants which have a non-selective mechanism of action (i.e. indiscriminate dissolution of 
the phospholipid membrane), poor selectivity is evident and they are likely too toxic for practical use 
with antifungal implantable materials. For non-clinically approved pharmaceuticals such as cationic 
small molecules (i.e. quaternary ammonium compounds, cationic peptides), it is unclear whether 
these would possess a sufficiently low degree of toxicity against human cells. In addition to the 
different cell membrane composition and metabolism mentioned above, fungi and bacteria operate 
by different metabolic processes. Finally, as we mentioned earlier, mammalian cell toxicity needs to 
be evaluated using more relevant cell types. Haemolysis is often used as a benchmark for 
mammalian cell toxicity; however, as a model system, red blood cells may not be a perfect model to 
test implantable devices that will contact tissue, as they lack mitochondria and nuclei. For example, 
with antifungal peptides, internalization and compartmentalization within vesicles have been shown 
to be an important factor beyond just how they bind to membranes (Muñoz et al., 2013; Muñoz et 
al., 2012). Furthermore, the solution (medium) that cells are cultured in (i.e. PBS versus cell culture 
solutions) have been shown to change the interpretation of toxicity of antifungal peptides 
(Helmerhorst et al., 1999). Lastly, modelling studies have revealed that the cell density is also an 
important factor when considering toxicity of cationic antimicrobials (Bagheri et al., 2015). Relevant 
(metabolically active) cell types and in vivo testing are required for comprehensive evaluation of 
potential antifungal biomaterials. 
4.6 Scale-up and manufacturing  
Researchers in applied scientific research ought to keep in mind the steps and limitations to 
successfully translate an idea from a laboratory bench to a commercial product; scale-up potential 
and ease of manufacturing are key issues to be addressed. These issues are of importance as certain 
procedures are relatively difficult on a small laboratory scale but commonly used in industrial 
settings (e.g. high-pressure and -temperature procedures), with the opposite true as well: Reagents 
and reaction times which are feasible in a research setting might be too costly and/or wasteful in an 
industrial setting (Reisman, 1993). Hence, attention needs to be paid to the following aspects.  
Process type: Whereas most processes in the laboratory are done in batches, industrial 
operations prefer continuous fabrications due to financial and safety concerns (Lee and Lee, 2014). 
Industrial-scale batch processes are only feasible for high-value products, which is the case for most 
medical devices. Hence, having to use a (semi-)batch process for medical devices is not inherently a 
deal breaker as demonstrated in the case of plasma treatment of contact lenses (Der Haegen Harro 
Mueller et al., 1995 ; Yasuda et al., 1975). 
Chemicals used: The use of “exotic” reagents for research purposes presents little obstacle 
whereas it needs to be avoided on an industrial scale. Furthermore, reduced use of solvents, or their 
omission altogether, has clear economic and ecological benefits on a large production scale. Hence, 
solvent-free thin film deposition methods such as PVD, CVD and PECVD are widespread and well 
established in industry (Oehr et al., 2017). 
Reproducibility / Homogeneity:  One key aspect of concern is the human factor in the 
equation. Whereas most labour on a laboratory scale is conducted by human operators, 
mechanisation and automation are the norm on an industrial scale. Such automation by robots 
brings about better reproducibility and precision (e.g. dip coating at a well-defined speed) (Puetz 
and Aegerter, 2004) but reduces process flexibility (e.g. change of the substrate’s shape and size). 
Furthermore, for most coatings homogeneity is another key aspect. Methods that yield good 
homogeneity on a small laboratory scale, such as spin coating (Norrman et al., 2005), may be 
difficult if not impossible to translate onto larger substrates in an industrial setting. Furthermore, 
certain deposition methods, such as vacuum based depositions, are highly process dependent and 
require re-optimisation when translated from a small to a larger scale operation (Whittle et al., 
2013). 
In summary, almost no laboratory process can be scaled up to an industrial grade operation 
by simply “enlarging” all aspects involved. Many, if not most of these aspects have a finitely scalable 
region in which they operate and do so well. Hence, researchers who want to conduct translatable 
research need to keep the hurdles of scale-up and manufacturing in mind. Otherwise, their invention 
in the laboratory might never grow beyond that small scale.   
5.0 Summary and future outlook 
It is clear from the extensive literature on clinical studies of infections associated with 
biomedical devices and implants that the use of such devices carries a substantial risk of serious 
complications that arise from microbial biofilms that form on surfaces of devices and implants and 
once formed, are difficult to eradicate. Moreover, such device-associated infections serve as nuclei 
for systemic infections. It is also clear from the literature that fungal species can play a major role in 
such surface-associated biofilm infections, either by themselves or in polymicrobial communities 
together with bacteria. While much research has focused on studying and trying to prevent bacterial 
biofilm formation on devices and implants, analogous work aimed at fungal biofilm infections is 
more recent and much more limited in volume. However, device-associated fungal biofilm infections 
are predominantly formed by Candida spp., which are causative of serious complications and a high 
mortality rate if they spawn a blood-borne infection (candidemia). 
Prevention of formation of biofilms on medical devices and implants is an unmet clinical 
need that calls for materials that can resist colonization by fungal (and bacterial) biofilms. 
Unfortunately, materials currently available for the fabrication of biomedical devices and implants 
are readily colonized – in fact, microbes have an amazing ability to attach to and thrive on a wide 
range of synthetic materials, from metals and ceramics to polymers. This probably represents an 
evolutionary advantage. Thus, it is a considerable research challenge to design and fabricate 
materials and devices that can resist microbial colonization. At present there are no devices and 
implants that effectively deter biofilm infections.  
Given the challenges in clinical treatment of biofilms once they have established on devices, 
the challenge is for biomaterials scientists and engineers to develop devices that prevent the initial 
attachment of microbes and thus eliminate the first step in infectious biofilm formation. Given that 
manufacturers have optimized the materials properties for devices and implants, for example the 
strength of hip implants and the flexibility of vascular grafts, rather than replacing entire materials it 
seems more promising to change the surface chemistry of existing materials, or apply thin coatings, 
to confer antimicrobial efficacy. A number of strategies have been explored to prevent fungal biofilm 
formation but to date, none has reached clinical usage. 
Key limiting factors are that there is a rather limited number of antifungal drugs available 
that can be used to fabricate such coatings and that it is difficult to predict the effects of such 
coatings on human cells (and thus possible adverse effects on human tissue apposite to an implant). 
The toxicity of antifungal drugs is tested in systemic administration and this does not allow 
extrapolation to how a drug would affect human cells and tissue when drug molecules are bound to 
a device surface. This issue needs to be better understood to enable rational design of antifungal 
coatings. 
But probably the biggest challenge is in translation from in vitro data to prediction of likely 
clinical performance. Novel antifungal materials, surfaces and coatings are tested using protocols 
that comprise the use of fungal cells in suspension and assessing their ability to attach onto surfaces 
and progress towards biofilm formation. Such testing is an enormous simplification of the in vivo 
situation where the formation of infectious biofilms proceeds within a complex biological 
environment, such as wound healing. It is no surprise then that for many antimicrobial materials, 
promising in vitro data were not matched by in vivo performance; failure of antimicrobial coatings to 
deliver adequate performance in animal models and clinical studies has been all too common and 
the reason why none is yet in commercial usage. Given the expense of in vivo testing, an urgent 
need is obvious for developing more realistic – and necessarily more complex - in vitro models for 
the formation of fungal biofilms on medical devices. 
Yet, given the toll that fungal biofilm infections continue to take, research on novel 
strategies to prevent fungal biofilm formation on medical devices is an absolute necessity. Novel 
strategies must be based on understanding of specific fungal metabolic pathways that can be 
addressed without side effects on human cell metabolism, such as distinct pathways of formation of 
fungal cell wall components, and on effective collaboration between microbiologists, materials 
scientists/engineers, and clinical researchers to ensure that molecular biology targets are translated 
to effective materials/coatings strategies and appropriate in vitro and clinical testing modalities. 
5.1 Short-term outlook 
The next five years will bring increasing awareness to the following important points.  
 Fungal and polymicrobial infectious biofilms can form on a wide range of medical 
devices and implants and, once formed, are difficult to eradicate, often requiring 
replacement of the device. 
 The main device-associated human biofilm pathogens are Candida species, 
particularly Candida albicans. If they spawn daughter cells from biofilms, serious 
blood infections can result. 
 A number of strategies have been pursued to equip surfaces of materials/devices 
with the ability to reduce or prevent the attachment of fungal cells and ensuing 
biofilm formation, but none has yet found usage on medical devices. 
 One class of strategies is based on releasing antifungal drugs from medical devices; 
this has short-lived efficacy and raises the question of the fate, distribution, and 
possible accumulation of released drug molecules. 
 Another class of strategies is based on permanently binding drug molecules onto the 
surfaces of medical devices and relying on the ability of such surface-bound drug 
molecules to kill fungal cells before they can attach onto the device. This approach, 
while attractive from a regulatory point of view, requires in-depth materials science 
and also can be affected by drugs no longer being able to exert antifungal activity 
when bound to a device (as opposed to being freely diffusible into the cytosol). 
 It might be worthwhile to pursue research into materials that use a combination of 
these strategies. Dual mechanism materials would compensate for detriments of 
each strategy alone. However, the regulatory framework for devices that have 
multiple functions is demanding. 
5.2 Long term outlook 
While a number of studies have reported substantial reductions in fungal biofilm formation 
in in vitro tests, analogous performance in animal and clinical studies has not been achieved. It is 
evident that the currently used in vitro models are far too simplistic and do not enable prediction of 
in vivo outcomes. This shortcoming is a big hurdle for rational progress, and more realistic test 
modalities should be a high priority in research on anti-infective devices. 
A major issue also is selectivity: how can one ensure effective deterrence of fungal 
attachment while ensuring that the same device surface interacts benignly with human cells and 
tissue? The use of highly selective antifungal drugs that target a specific, cell wall-associated fungal 
metabolic process seems indicated. 
It is essential to perform detailed analysis of antifungal surfaces and coatings to ensure that 
they are indeed what they were intended to be and hence observed biological responses can be 
interpreted reliably and with confidence in terms of chemical and physical properties of the surface 
of the device. A key question when binding antifungal drugs onto device surfaces is to ensure that all 
molecules are indeed covalently anchored, lest some of them will drift away from the surface when 
placed in a biological test environment. 
In conclusion, there is a clear need to address the clinical problem of the formation and 
maturation of fungal or mixed bacterial/fungal biofilms on biomedical devices. Such research is 
increasing rapidly. Based on molecular microbiological understanding of specific fungal metabolic 
pathways, collaboration between microbiologists, biomaterials scientists, and clinicians can be 
expected to lead to the development of coatings that will selectively deter biofilm formation while 
not causing adverse effects on human cells and tissue. While manufacturability, regulatory 
guidelines, and cost will all need to be considered in the scale-up of laboratory-scale coatings, we 
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